Deciphering a subgroup of breast carcinomas with putative progression of grade during carcinogenesis revealed by comparative genomic hybridisation (CGH) and immunohistochemistry.
Distinct parallel cytogenetic pathways in breast carcinogenesis could be identified in recent years. Nevertheless, it remained unclear as to which tumours may have progressed in grade or which patterns of cytogenetic alteration may define the switch from an in situ towards an invasive lesion. In order to gain more detailed insights into cytogenetic mechanisms of the pathogenesis of breast cancer, the chromosomal imbalances of 206 invasive breast cancer cases were characterised by means of comparative genomic hybridisation (CGH). CGH data were subjected to hierarchical cluster analysis and the results were further compared with immunohistochemical findings on tissue arrays from the same breast cancer cases. The combined analysis of immunohistochemical and cytogenetic data provided evidence that carcinomas with gains of 7p, and to a lesser extent losses of 9q and gains of 5p, are a distinct subgroup within the spectrum of ductal invasive grade 3 breast carcinomas. These aberrations were associated with a high degree of cytogenetic instability (16.6 alterations per case on average), 16q-losses in over 70% of these cases, strong oestrogen receptor expression and absence of strong expression of p53, c-erbB2 and Ck 5. These characteristics provide strong support for the hypothesis that these tumours may develop through stages of well- and perhaps intermediately differentiated breast cancers. Our results therefore underline the existence of several parallel and also stepwise progression pathways towards breast cancer.
Korsching
E
E
Institute of Pathology, University of Münster, Domagkstr. 17, 48149 Münster, Germany.
Packeisen
J
J
Helms
M W
MW
Kersting
C
C
Voss
R
R
van Diest
P J
PJ
Brandt
B
B
van der Wall
E
E
Boecker
W
W
Bürger
H
H
D001943:Breast Neoplasms / Q000235:genetics*; D002278:Carcinoma in Situ / Q000235:genetics; D044584:Carcinoma, Ductal / Q000235:genetics*; D002869:Chromosome Aberrations; D016000:Cluster Analysis; D005260:Female; D005434:Flow Cytometry; D018734:Genes, erbB-2; D006801:Humans; D007150:Immunohistochemistry; D009693:Nucleic Acid Hybridization; D011980:Receptors, Progesterone / Q000378:metabolism
D011980:Receptors, Progesterone